Intervention Cuts STI Rates Among Black Women

BY SUSAN LONDON
Contributing Writer

MEXICO CITY — African American women who receive an intervention that includes a package of safer-sex options have a large reduction in the incidence of sexually transmitted infections relative to peers who receive general health promotion, researchers reported at the International AIDS Conference.

Among women in the U.S., marked racial as well as regional disparities (in HIV incidence) exist,” said lead author Gina M. Wingood, Sc.D., of Emory University in Atlanta. “Specifically, women in the deep southern U.S. are severely affected.” A re- searcher who received a grant from the National Institutes of Health to study reproductive health among women in the deep south, Wingood said, the intervention, delivered in two 4-hour workshops, focused on providing education and training in the use of condoms and penile-vaginal sex, giving women few preventive options.

To address these issues, Dr. Wingood and her colleagues undertook the STARS (Sisters Talking About Real Solutions) trial. With the database of a health maintenance organization in Georgia, they ran- ked women based on the number of sexual partners they reported. Women with fewest partners were invited to participate. Participating women were randomly assigned to an intervention group or a comparison group.

The intervention, delivered in two 4-hour workshops, focused on fostering ethnic and gender pride (to enhance self-esteem, self-worth, and healthy relationships), increasing awareness of healthy and unhealthy relationships (to address the link between abuse and sexually transmitted infections), and introducing a package of safer-sex options known as AMOUR (Abstain from unsafe sex and douching; Mutual stimulation; nonpenetrative sex; Oral sex with protection; Uninfected partners, referring to ensuring that partners do not have STIs; and Regular condom use and reduction of number of partners). The comparison group received a single 4-hour workshop that focused on general health promotion.

The women enrolled in the trial were a mean age of 24 years; 57% lived with a family member, 88% had completed high school, and 86% were in relationships lasting an average of 23 months. Intention-to-treat analyses were based on 605 women in the intervention group and 243 women in the comparison group. The workshops were completed by 96% and 100%, respectively, and 75% of women in each group completed the trial’s 12-month follow-up assessment.

In terms of biologic outcomes at 12 months, women in the intervention group were significantly less likely to have acquired any of four STIs studied (human papillomavirus type 16 or 18, chlamydia, gonorrhea, or trichomoniasis) relative to their counterparts in the comparison group (odds ratio, 0.35). In addition, intervention women were significantly less likely to have acquired human papillomavirus infection individually (O.R. 0.37) and the other, nonviral STIs individually (O.R. 0.62).

Women in the intervention group had significantly more favorable levels of each of nine risk behaviors than did the comparison group. For example, they were more likely to have asked their main partner to be tested for STIs (O.R. 1.41) and to have had protected oral sex (O.R. 2.05), and they were less likely to have douched (O.R. 0.38) and to have had sex with more than one partner (O.R. 0.73) or with casual partners (O.R. 0.66).

Researchers Rebound From Latest AIDS Vaccine Failure

BY SUSAN LONDON
Contributing Writer

MEXICO CITY — The development of an AIDS vaccine is likely to take a long time, and research needs to be more selective on the most promising candidates, given the recent failure of the latest leading candidate to prevent infection in a large international trial, according to the findings of a report aimed at setting priorities for AIDS vaccine research.

Experts at the International AIDS Conference discussed the status of AIDS vaccine efforts at a press conference to unveil the AIDS Vaccine Blueprint 2008. The document, published by the International AIDS Vaccine Initiative (IAVI), is the fifth biennial report of its kind. It comes at a time when optimism in the field is fading after early closure of the trial, failure of the last vaccinated year and cancellation of the PAVE 100 trial of a new vaccine this year.

The blueprint delineates the current challenges in developing an AIDS vaccine, and provides interim milestones for the pipeline. “We believe that the majority of the 30-odd candidates that are in the pipeline should be prioritized based on their probability of success,” he said. This recommendation is not new, he acknowledged, but the document goes further, detailing how it should be done by requiring vaccine candidates to be superior to ones that have failed in preclinical testing.

In recent years, more stakeholders have rallied behind the blueprint, which will be critical going forward, according to Dr. Berkerley, executive director of the IAVIDS in Geneva. “This [AIDS vaccine development] is not going to be something that can be done by one organization. It requires a coalition,” he said.

Science is never a straight line. Failure is part of the game,” noted Dr. Alan Berkley, executive director of the Global HIV Vaccine Enterprise in New York. As disappointing as the STEP trial’s results were, the trial has been a success in the sense that it provided, and continues to provide, a wealth of data that will help inform future trials.

Given the retroviral nature of HIV and the lack of much precedence in developing vaccines against retroviruses, he applauded recent efforts by several organizations to formulate diverse approaches to the problem.

Putting the AIDS vaccine effort into context, Dr. Berkley noted that the development of a vaccine typically takes decades. Advancing HIV vaccine research will require not only new talent, but also stable, predictable, and flexible financing, he continued. Flexibility is important because “we need to be able to jump on advances and quickly drop things that aren’t working,” he said. “It will be critical to maintaining incentives that keep companies engaged in the effort.”

In response to calls to end the vaccine research effort, Dr. Piot cited the diseases’ staggering toll. “If the world can be satisfied with 2.7 million people infected per year—7,500 per day—then I am not so sure where the standards are for declaring something a total disaster,” he said.

Shutting down the AIDS vaccine trial sites in Africa would be “a big mistake,” agreed Dr. Omu Anzala, chairman of microbiology at the University of Nairobi (Kenya) and director of the Kenya AIDS Vaccine Initiative (IAVI). He noted that these sites not only stand ready for future trials, but also continue to conduct epidemiological and basic HIV research. “It is this information that will then feed into HIV vaccine discovery and also feed into drug discovery,” he said.

Dr. Anzala agreed with his colleagues that the failure of a single vaccine is not cause for condemning the entire AIDS vaccine initiative. Noting that he comes from a country known for long-distance running, he likened the search for an effective vaccine to a marathon in which perhaps 100 runners start and many fall by the wayside, but eventually one wins. “We cannot stop now,” he concluded.